Australia markets closed

Cocrystal Pharma, Inc. (8CC.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.3800-0.0300 (-2.13%)
As of 08:25AM CEST. Market open.

Cocrystal Pharma, Inc.

19805 North Creek Parkway
Bothell, WA 98011
United States
305 425 1780
https://www.cocrystalpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12

Key executives

NameTitlePayExercisedYear born
Dr. Roger D. Kornberg Ph.D.Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board121.51kN/A1947
Dr. Sam Lee Ph.D.Co-Founder, Co-CEO & President523.24kN/A1960
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Corporate governance

Cocrystal Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.